Replimune Group (NASDAQ:REPL) Stock Price Down 5.4% – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL) shares traded down 5.4% during mid-day trading on Thursday . The company traded as low as $7.36 and last traded at $7.2950. 522,393 shares traded hands during trading, a decline of 50% from the average session volume of 1,043,914 shares. The stock had previously closed at $7.71.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on REPL shares. Leerink Partnrs raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Piper Sandler raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a research note on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $4.00 to $18.00 in a research note on Monday, October 20th. Finally, HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Replimune Group Stock Down 7.7%

The company’s 50 day simple moving average is $9.40 and its 200-day simple moving average is $7.56. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $558.04 million, a P/E ratio of -2.05 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Research analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total value of $111,300.00. Following the completion of the sale, the chief executive officer owned 333,576 shares of the company’s stock, valued at $3,712,700.88. The trade was a 2.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Konstantinos Xynos sold 7,248 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the sale, the insider owned 139,685 shares of the company’s stock, valued at approximately $1,271,133.50. This trade represents a 4.93% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 25,625 shares of company stock valued at $257,607. Corporate insiders own 5.20% of the company’s stock.

Institutional Trading of Replimune Group

Several large investors have recently added to or reduced their stakes in REPL. Fcpm Iii Services B.V. raised its position in Replimune Group by 6.4% in the third quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock worth $17,424,000 after acquiring an additional 248,672 shares during the period. Vanguard Group Inc. raised its holdings in Replimune Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after purchasing an additional 9,707 shares during the period. Braidwell LP lifted its position in Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares in the last quarter. Balyasny Asset Management L.P. grew its holdings in Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares during the period. Finally, Readystate Asset Management LP grew its holdings in Replimune Group by 1,296.2% during the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after purchasing an additional 2,433,292 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.